No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 31 of the 35 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 37
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Grace Therapeutics, Inc. (GRCE) stock was $2.13 as of Oct 6, 2026, 1:44 PM EDT, up 3.16% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -31.9%
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada.
Biotechnology · Princeton, NJ
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.15
Revenue Est.
$1.00M
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.18
Revenue
$0.00
vs Estimate
$400000.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GRCE | $34.58M | $2.13 | +3.16% | -31.89% | N/A | N/A | N/A |
| 2BCTX | $34.97M | $4.02 | -3.83% | -67.87% | -67.32% | -52.81% | vs GRCE |
| 3ELUT | $34.04M | $0.77 | -6.28% | -6.61% | -33.96% | N/A | vs GRCE |
| 4ARAY | $33.69M | $0.28 | -6.13% | -82.00% | -39.94% | -25.77% | vs GRCE |
| 5EUDA | $33.63M | $18.01 | +4.12% | -61.04% | N/A | N/A | vs GRCE |
| 6DCGO | $35.76M | $0.36 | -0.82% | -71.09% | -48.40% | N/A | vs GRCE |
forward FY estimate
N/A
Consensus Rating
Based on 2 analysts
Average Price Target
$5.85
+175.4% upside
Low
$3.89
Current
$2.13
High
$7.81
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Quarter ending Dec 2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Quarter ending Mar 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Quarter ending Jun 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-0.71 | $-0.68 | $-0.64 | 1 |
| FY 2028 | $-0.50 | $-0.47 | $-0.43 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.00M | $1.00M | $1.00M | 1 |
| Quarter ending Dec 2026 | $2.30M | $2.30M | $2.30M | 1 |
| Quarter ending Mar 2027 | $3.50M | $3.50M | $3.50M | 1 |
| Quarter ending Jun 2027 | $4.50M | $4.50M | $4.50M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $4.83M | $5.00M | $5.17M | 1 |
| FY 2028 | $4.96M | $5.00M | $5.04M | 2 |
